OncoMatch/Clinical Trials/NCT07167446
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Is NCT07167446 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Cannabidiol (CBD) and oxaliplatin-based chemotherapy for oxaliplatin induced peripheral neuropathy in cancer patients.
Treatment: Cannabidiol (CBD) · oxaliplatin-based chemotherapy — This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (oxaliplatin) — metastatic
planned to receive Ox based chemotherapy in metastatic setting (at least 3 months planned). Subjects are allowed to have one cycle of Ox based chemotherapy before enrollment.
Cannot have received: platinum-based chemotherapy
Exception: Subjects are allowed to have one cycle of Ox based chemotherapy before enrollment.
No prior platinum exposure
Lab requirements
Blood counts
appropriate for systemic therapy, as per physician's discretion
Kidney function
appropriate for systemic therapy, as per physician's discretion
Liver function
Total Bilirubin: <= 1.5 X ULN; AST(SGOT)/ALT(SGPT): <= 3 X ULN (5 X ULN in patients with liver metastases)
Patients must have marrow and organ function appropriate for systemic therapy, as per physician's discretion, but liver function should meet criteria below: Total Bilirubin: less than and/or equal to 1.5 X ULN; AST(SGOT)/ALT(SGPT): less than and/or equal to 3 X ULN (5 X ULN in patients with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify